We practice pharmaceutical care in its entirety, with the patients and customers at the center of all we do. We offer state-of-the-arts care in our brick-and-mortar premises in Lagos, as well as virtually through phone counseling sessions as well as online sales services. We value health
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsvaerd, Denmark, with production facilities in seven countries, and affiliates or offices in 75 countries.
Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.
Novo Nordisk employs more than 40,000 people globally, and marketed its products in 180 countries. It is the largest publicly traded company in the Nordic countries by market capitalization. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.
Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. Novo Nordisk was ranked 72nd on "Fortune’s 100 Best Companies to Work ForÂ®” list within the U.S. state of New Jersey as of January 2014.
No review available Do you currently work in this company or maybe have worked there before? Drop a review
Novo Nordisk Salaries
Anonymously drop your salary if you are working with this company or maybe have worked with them in the past.Drop your salary
Subscribe to Job Alert
Join our happy subscribers